Correlation between serial measurements of N‐terminal pro brain natriuretic peptide and ambulatory cardiac filling pressures in outpatients with chronic heart failure
暂无分享,去创建一个
Astrid Fahrleitner-Pammer | Stefano Ghio | Frieder Braunschweig | F. Braunschweig | P. Fotuhi | C. Linde | S. Ghio | U. Hoppe | A. Fahrleitner-Pammer | Maurizio Mangiavacchi | Parwis Fotuhi | Uta C Hoppe | Cecilia Linde | M. Mangiavacchi
[1] A. Maisel,et al. B-type natriuretic peptide in the diagnosis and management of congestive heart failure. , 2001, Cardiology clinics.
[2] K. Kugiyama,et al. Localization and Mechanism of Secretion of B‐Type Natriuretic Peptide in Comparison With Those of A‐Type Natriuretic Peptide in Normal Subjects and Patients With Heart Failure , 1994, Circulation.
[3] M. Redfield,et al. The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. , 2002, Journal of cardiac failure.
[4] L. Rydén,et al. Continuous ambulatory haemodynamic monitoring with an implantable system. The feasibility of a new technique. , 1998, European heart journal.
[5] L. Lenert,et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. , 2001, Journal of the American College of Cardiology.
[6] R C Littell,et al. Mixed Models: Modelling Covariance Structure in the Analysis of Repeated Measures Data , 2005 .
[7] F. Braunschweig,et al. Continuous Hemodynamic Monitoring in Heart Failure , 2002, Journal of cardiovascular electrophysiology.
[8] L. Rydén,et al. Monitoring of pulmonary arterial diastolic pressure through a right ventricular pressure transducer. , 1995, Journal of cardiac failure.
[9] M. Pfeffer,et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. , 2002, Journal of the American College of Cardiology.
[10] H. Hense,et al. Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. , 1998, Journal of the American College of Cardiology.
[11] D. Murdoch,et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. , 1999, American heart journal.
[12] M. Kinoshita,et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. , 1998, American heart journal.
[13] N. Freemantle,et al. Clinical trials update from the American College of Cardiology meeting: CARE‐HF and the Remission of Heart Failure, Women's Health Study, TNT, COMPASS‐HF, VERITAS, CANPAP, PEECH and PREMIER , 2005, European journal of heart failure.
[14] M. Quiñones,et al. Optimal Noninvasive Assessment of Left Ventricular Filling Pressures: A Comparison of Tissue Doppler Echocardiography and B-Type Natriuretic Peptide in Patients With Pulmonary Artery Catheters , 2004, Circulation.
[15] L. Stevenson,et al. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. , 1989, JAMA.
[16] Alan S Maisel,et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. , 2002, The New England journal of medicine.
[17] E. Shapiro,et al. Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit , 2005 .
[18] L. Rydén,et al. Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. , 2003, Journal of the American College of Cardiology.
[19] L. Lenert,et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. , 2001, Journal of the American College of Cardiology.
[20] R. T. Lie,et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. , 1996, Circulation.
[21] M. Kinoshita,et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. , 2001, Journal of the American College of Cardiology.
[22] J. Burnett,et al. BNP: pathophysiological and potential therapeutic roles in acute congestive heart failure. , 1997, The American journal of physiology.
[23] P. Krishnaswamy,et al. Stability of B-type natriuretic peptide levels during exercise in patients with congestive heart failure: implications for outpatient monitoring with B-type natriuretic peptide. , 2002, American heart journal.
[24] Philip Adamson,et al. Continuous ambulatory right heart pressure measurements with an implantable hemodynamic monitor: a multicenter, 12-month follow-up study of patients with chronic heart failure. , 2002, Journal of cardiac failure.
[25] F. Marumo,et al. Plasma human brain natriuretic peptide in chronic renal failure. , 1995, Clinical nephrology.
[26] R. Wilson,et al. Measurement of pulmonary artery diastolic pressure from a right ventricular pressure transducer in patients with heart failure. , 1996, Journal of cardiac failure.
[27] O. Vuolteenaho,et al. Involvement of transcriptional and posttranscriptional mechanisms in cardiac overload-induced increase of B-type natriuretic peptide gene expression. , 1997, Circulation research.
[28] J. Potter,et al. Value of B-type natriuretic peptide for identifying significantly elevated pulmonary artery wedge pressure in patients treated for established chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. , 2005, The American journal of cardiology.
[29] Douglas W Mahoney,et al. Plasma brain natriuretic peptide concentration: impact of age and gender. , 2002, Journal of the American College of Cardiology.
[30] C. Frampton,et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations , 2000, The Lancet.
[31] P. Ivarsen,et al. A new, fast and reliable radioimmunoassay of brain natriuretic peptide in human plasma. Reference values in healthy subjects and in patients with different diseases. , 1997, Scandinavian journal of clinical and laboratory investigation.